Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles

Area of Science:

• Virology
• Vaccinology
• Immunology

Background:

• Ebola virus (EBOV) causes severe hemorrhagic fever with no approved therapeutics or vaccines.
• Ebola virus-like particles (VLPs) are immunogenic and protective, showing promise as vaccine candidates.
• Recombinant viral vectors, like Modified Vaccinia virus Ankara-Bavarian Nordic (MVA-BN), offer a safe platform for vaccine development.

Purpose of the Study:

• To develop a novel vaccine strategy using a recombinant MVA-BN vector to produce noninfectious EBOV VLPs.
• To assess the immunogenicity and VLP production capabilities of the MVA-BN-EBOV-VLP construct.
• To evaluate the potential for developing multivalent VLP-producing MVA-based filovirus vaccines.

Main Methods:

• Constructed a recombinant MVA-BN coexpressing EBOV VP40, GP, and TAFV NP (MVA-BN-EBOV-VLP).
• Analyzed VLP production and composition in infected human cells.
• Assessed EBOV GP-specific humoral and cellular immune responses in immunized mice.

Main Results:

• MVA-BN-EBOV-VLP infected cells produced authentic EBOV VLPs decorated with GP spikes.
• Comparable GP expression and cell surface transport were observed between MVA-BN-EBOV-VLP and MVA-BN-EBOV-GP.
• The construct induced comparable EBOV GP-specific CD8 T cell responses and antibody levels in mice.

Conclusions:

• MVA-BN-EBOV-VLP successfully generates noninfectious EBOV VLPs, serving as a potent immunogen.
• The vaccine candidate efficiently induced both humoral and cellular immune responses against Ebola virus.
• This platform supports future development of multivalent filovirus vaccines by incorporating diverse antigens.